This finding does, however, warrant further exploration of lithium carbonate in a well-balanced, blinded, randomized clinical trial specifically targeted at patients with ALS and the UNC13A C/C genotype. This evidence concerns the gene UNC13A and amyotrophic lateral sclerosis.